Cartesian Therapeutics, Inc.RNACNASDAQ
Loading
Year-over-year operating cash flow growth rate
Latest
-13.54%
↑ 55% vs avg
Percentile
P38
Within normal range
Streak
2 qtr
Consecutive declineDecelerating
Average
-29.98%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | -13.54% |
| Q3 2025 | 10.96% |
| Q2 2025 | 24.18% |
| Q1 2025 | -230.02% |
| Q4 2024 | -151.14% |
| Q3 2024 | 194.77% |
| Q2 2024 | 9.24% |
| Q1 2024 | 31.65% |
| Q4 2023 | -152.70% |
| Q3 2023 | 6.87% |
| Q2 2023 | -12.89% |
| Q1 2023 | 26.03% |
| Q4 2022 | -372.20% |
| Q3 2022 | 135.47% |
| Q2 2022 | -3.43% |
| Q1 2022 | 62.29% |
| Q4 2021 | -192.76% |
| Q3 2021 | -77.83% |
| Q2 2021 | 50.19% |
| Q1 2021 | -67.35% |
| Q4 2020 | -111.05% |
| Q3 2020 | 655.87% |
| Q2 2020 | -0.94% |
| Q1 2020 | 9.15% |
| Q4 2019 | -15.77% |
| Q3 2019 | -54.54% |
| Q2 2019 | 64.44% |
| Q1 2019 | -58.77% |
| Q4 2018 | 20.48% |
| Q3 2018 | 5.55% |
| Q2 2018 | -26.58% |
| Q1 2018 | -5.82% |
| Q4 2017 | 17.90% |
| Q3 2017 | -79.19% |
| Q2 2017 | 43.76% |
| Q1 2017 | -1084.32% |
| Q4 2016 | 128.47% |
| Q3 2016 | 2.51% |
| Q2 2016 | 44.85% |
| Q1 2016 | -33.06% |